Engineered LINE-1 retrotransposition in nondividing human neurons
Metadata
Show full item recordAuthor
Alejandro Rubio; Macia, Angela; Widmann, Thomas J.; Rodríguez Heras, Sara; Ayllon, Verónica; Sánchez, Laura; Benkaddour-Boumzaouad, Meriem; Muñoz López, Martin; Vedia Rubio, Alejandro; Amador Cubero, Suyapa; Blanco Jiménez, Eva; Menéndez, Pablo; García Pérez, José LuisEditorial
Cold Spring Harbor Lab Press
Date
2020-06-15Referencia bibliográfica
Macia, A., Widmann, T. J., Heras, S. R., Ayllon, V., Sanchez, L., Benkaddour-Boumzaouad, M., ... & Garcia-Castro, J. (2017). Engineered LINE-1 retrotransposition in nondividing human neurons. Genome research, 27(3), 335-348. [DOI: 10.1101/gr.206805.116]
Sponsorship
United States Department of Defense BC051386; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Neurological Disorders & Stroke (NINDS) 1R03NS087290-01; ALS Therapy Alliance 2013-F-067; Marie Curie IRG project FP7-PEOPLE-2007-4-3-IRG: SOMATIC LINE-1; European Research Council (ERC) ERC-STG-2012-233764; Howard Hughes Medical Institute IECS-55007420; Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund (ISFF2); Plan Nacional de I+D+I FIS-FEDER-PI11/01489 FIS-FEDER-PI14/02152 PCIN-2014-115-ERA-NET NEURON II; CICE-FEDER-P09-CTS-4980; CICE-FEDER-P12-CTS-2256; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Neurological Disorders & Stroke (NINDS) R03NS087290; ICREAAbstract
Half the human genome is made of transposable elements (TEs), whose ongoing activity continues to impact our genome.
LINE-1 (or L1) is an autonomous non-LTR retrotransposon in the human genome, comprising 17% of its genomic mass and
containing an average of 80–100 active L1s per average genome that provide a source of inter-individual variation. New
LINE-1 insertions are thought to accumulate mostly during human embryogenesis. Surprisingly, the activity of L1s can further
impact the somatic human brain genome. However, it is currently unknown whether L1 can retrotranspose in other
somatic healthy tissues or if L1 mobilization is restricted to neuronal precursor cells (NPCs) in the human brain. Here,
we took advantage of an engineered L1 retrotransposition assay to analyze L1 mobilization rates in human mesenchymal
(MSCs) and hematopoietic (HSCs) somatic stem cells. Notably, we have observed that L1 expression and engineered retrotransposition
is much lower in both MSCs and HSCs when compared to NPCs. Remarkably, we have further demonstrated
for the first time that engineered L1s can retrotranspose efficiently in mature nondividing neuronal cells. Thus, these findings
suggest that the degree of somatic mosaicism and the impact of L1 retrotransposition in the human brain is likely much
higher than previously thought.